Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide added to induction chemotherapy and maintenance in newly diagnosed AML or high-risk MDS
NL-OMON20903Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (5 arms), sponsored by HOVON. Primary endpoints: Lenalidomide dose level selection, Event-free survival and 1 more. Started Mar 2014; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON20903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20903.